In the wake of several Risperdal trials going to verdict this year, parties on both sides of the litigation are contesting the amounts juries awarded.
In recent post-trial filings in two Risperdal cases, Janssen Pharmaceuticals has argued the verdicts, both of which were over $1 million, should be reduced. The plaintiff in a third case—the most recent to come to a verdict—is also contesting the $500,000 award in that case, arguing the court erred in foreclosing any future damages award.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
